RESEARCH ARTICLE

Surveying and Optimizing the Predictors for Ependymoma Specific Survival using SEER Data

Min Rex Cheung

Abstract

Purpose: This study used receiver operating characteristic curve to analyze Surveillance, Epidemiology and End Results (SEER) ependymoma data to identify predictive models and potential disparity in outcome. Materials and Methods: This study analyzed socio-economic, staging and treatment factors available in the SEER database for ependymoma. For the risk modeling, each factor was fitted by a Generalized Linear Model to predict the outcome (‘brain and other nervous systems’ specific death in yes/no). The area under the receiver operating characteristic curve (ROC) was computed. Similar strata were combined to construct the most parsimonious models. A random sampling algorithm was used to estimate the modeling errors. Risk of ependymoma death was computed for the predictors for comparison. Results: A total of 3,500 patients diagnosed from 1973 to 2009 were included in this study. The mean follow up time (S.D.) was 79.8 (82.3) months. Some 46% of the patients were female. The mean (S.D.) age was 34.4 (22.8) years. Age was the most predictive factor of outcome. Unknown grade demonstrated a 15% risk of cause specific death compared to 9% for grades I and II, and 36% for grades III and IV. A 5-tiered grade model (with a ROC area 0.48) was optimized to a 3-tiered model (with ROC area of 0.53). This ROC area tied for the second with that for surgery. African-American patients had 21.5% risk of death compared with 16.6% for the others. Some 72.7% of patient who did not get RT had cerebellar or spinal ependymoma. Patients undergoing surgery had 16.3% risk of death, as compared to 23.7% among those who did not have surgery. Conclusion: Grading ependymoma may dramatically improve modeling of data. RT is under used for cerebellum and spinal cord ependymoma and it may be a potential way to improve outcome.

Keywords: Ependymoma - SEER registry - radiotherapy - under usage - cause specific survival

Asian Pac J Cancer Prev, 15 (2), 867-870

Introduction

The Surveillance Epidemiology and End Results (SEER) cancer registry data have been extensively used to model outcome prediction models for ependymoma (McGuire et al., 2009) (Rodriguez et al., 2009) (Amirian et al., 2012) (Bishop et al., 2012). These studies are important in identifying disparity in treatment and build models for selecting patients for clinical trials. The cause specific survival rates for both childhood and adult with ependymoma are about 80% ((McGuire et al., 2009) (Rodriguez et al., 2009) (Amirian et al., 2012) (Bishop et al., 2012), and this study). Thus there is room for improvement. This study used receiver operating characteristic curve to analyze SEER ependymoma outcome data. The aim of this study was to identify and optimize predictive ependymoma models to aid treatment and patient selection. This study also examined why some predictive models may not work as expected.

Surveillance Epidemiology and End Results (SEER) (http://seer.cancer.gov/) is a public use cancer registry of United States of America (US). SEER is funded by National Cancer Institute and Center for Disease Control to cover 28% of all oncology cases in US. SEER started collecting data in 1973 for 7 states and cosmopolitan registries. Its main purpose is through collecting and distributing data on cancer, it strives to decrease the burden of cancer. SEER data are used widely as a benchmark data source for studying cancer outcomes in US and in other countries. The extensive ground coverage by the SEER data is ideal for identifying the disparity in oncology outcome and treatment in different geographical and cultural areas for cancers. In addition to the biological staging factors and the treatment factors, this database also contains a large number of county level socio-economic factors data. This study aimed to identify barriers to good treatment outcome that may be discernable from a national database.

Materials and Methods

SEER registry has massive amount of data available for analysis, however, manipulating this data pipeline could be challenging. SEER Clinical Outcome Prediction Expert (SCOPE) (Cheung, 2012) was used mine SEER data and construct accurate and efficient prediction models. The data were obtained from SEER 18 database. SEER is a public use database that can be used for analysis with no
Min Rex Cheung

Asian Pacific Journal of Cancer Prevention, Vol 15, 2014

There were 3500 patients included in this study (Table 1). The follow up (S.D.) was 79.8 (82.3) months. 46.5% of the patients were female. The mean (S.D.) age was 34.4 (22.8) years. There were 60% ependymoma patients listed from SEER database were adults. Patients younger than 20 years old has 27% risk of cause specific death compared with 12.5% for older patients (Table 2). Complete staging was nearly not done as a common practice. There is no significant female to male difference in risk of cause specific death (Table 2). A third of the patients had supratentorial ependymoma (‘Brain NOS’ and cerebral lobes). They had a 26.8% risk of cause specific death. Most of the tumors were not graded. Unknown grade has 15% risk of cause specific death compared to 9% for Grade I and II, 36% for grade III and IV. A 5-tiered Grade model (with a ROC area 0.48) was optimized to a 3-tiered model (with a ROC area of 0.53) by SCOPE (Cheung, 2012). This ROC area tied for the second with what was obtained for surgery (Table 1). Among the socioeconomic factors, African American patients had 21.5% risk of death compared with 16.6% of the others. However, this level of difference did not significantly increase the ROC area. For socioeconomic factors, county family income, county education attainment, and rural-urban were not a predictor of poor outcome (Tables 1 and 2). African-American patients had 21.5% risk of death compared with 16.6% of the others (Table 2).

There is about 17% risk of ependymoma death in SEER localized disease ependymoma patients (Table 2). Age older than 20 years old did correlate with higher percentage mortality during this study period from 1973 to 2009 (Table 1 and Table 2). Use of radiotherapy was not associated with a lower risk of cause specific mortality in the overall cohort (Table 2), but surgery was. Specifically, RT was associated with 23% risk of death, and 12.3% risk of death without RT, 61% patients had RT in cerebellar or
spinal ependymoma, but the same time, 72.7% of patient who did not get RT had cerebellar or spinal ependymoma. Patients had surgery had 16.3% risk of death, 23.7% risk of death among patients who did not have surgery. The use of RT has declined over the past 4 decades from about 75% usage to the current 30% usage (Figure 1). And this drop surprising is mostly associated with the very low usage of RT in the adult population (Figure 2) that may correlate with their poor outcome.

Discussion

This study is interested in constructing models that will aid patient and treatment selection for ependymoma cancer patients. To that end, this study examined the ROC models (Hanley and McNeil, 1982) of a long list of potential explanatory factors (Table 1). ROC models take into account both sensitivity and specificity of the prediction. Ideal model would have a ROC area of 1 and a random model is expected to have an area of 0.5 (Hanley and McNeil, 1982). For example, a clinical ROC model can be used to predict if a patient receiving the recommended treatment will die from the disease. Grade was the most predictive of patient outcome (Table 1). Grade has ROC of 0.61 was higher than the 0.53 of surgery. Thus making grade available in the pathology report may improve patient selection and council.

After binary fusion by SCOPE, the 5 tiered grade was reduced to a 3 tiered grade based on ROC area calculations (Table 1). Unk grade was associated with intermediate risk of cause specific death (Table 2). However, there is no a priori reason to put it between grade I and IV. Thus it was left as a high risk factor. The solution to the uncertainty of placement of these cases is to complete the grading. The binary fusion was performed to demonstrate how a complex predictive model could be numerically optimized to a much simpler model that may also be useful.

When there are competing prediction or prognostic models, the most efficient (i.e. the simplest) model is thought to prevail (D’Amico et al., 1998). This has an information theoretic under-pinning. For practical purposes, simpler models require fewer patients for a randomized trials because fewer risk strata need to be balanced. In the clinic, simpler models are easier to use. SCOPE streamlined ROC models by binary fusion (Table 1). Two adjacent strata were tested iteratively to see if they could be combined without sacrificing the higher predictive power usually belong to the more complex models. This study has shown that SCOPE can built efficient and accurate prediction models.

For radiotherapy, the ROC area of 0.58 was modestly more than 0.5. For a point of reference, using we computed the prostate risk model was 0.75 in its accuracy of predicting biochemical failure(Cheung et al., 2001a, b). Low ROC areas imply the information content (i.e. the staging accuracy) of the models may be limited. It is consistent with the fact that most patients did not have complete grading or staging (Table 2). This is an area for potential improvement.

Ependymoma is an aggressive disease, there was a 17% risk of ependymoma death (Table 2) despite treatments. There was only 30% use of RT even when the indication for RT was clear as for the cerebellar and spinal cord ependymoma (Koshy et al., 2011). Furthermore, more adult patients than pediatric patients did not get RT (Figure 2) and therefore did not get the benefit of RT. Thus radiation oncologists should be more attentive in recommending RT for these patients. For the pediatric populations, proton use is expected to improve

Table 2. Risk of Cause Specific Mortality (%) Associated with Different Models

| Variables            | Category            | Number | Expected |
|----------------------|---------------------|--------|----------|
| Age of diagnosis     | < 20 years          | 1,080  | 0.27     |
|                      | ≥ 20 years old      | 2,420  | 0.13     |
| Sex                  | Female              | 1,626  | 0.15     |
|                      | Male                | 1,874  | 0.19     |
| Site                 | Brain               | 2,099  | 0.26     |
|                      | Cranial Other       | 1,401  | 0.04     |
| Primary site         | Brain NOS           | 1,134  | 0.27     |
|                      | Cerebellum etc      | 2366   | 0.12     |
| Grade                | Well I              | 199    | 0.12     |
|                      | Mod II              | 456    | 0.07     |
|                      | Poor III            | 90     | 0.38     |
|                      | Undiff IV           | 397    | 0.35     |
|                      | Unknown             | 2,358  | 0.15     |
| Home                 | Rural-Urban         | 3,149  | 0.17     |
|                      | Others              | 351    | 0.18     |
| Family Income        | ≥ $50000            | 2,160  | 0.16     |
|                      | < $50000            | 1,340  | 0.18     |
| College graduate     | ≥ 25 %              | 1,893  | 0.17     |
|                      | < 25 %              | 1,607  | 0.17     |
| Race                 | White/others        | 3,122  | 0.17     |
|                      | Black               | 288    | 0.22     |
| Radiation            | Beam radiation      | 1,473  | 0.23     |
|                      | Others              | 2,026  | 0.12     |
| Surgery              | Yes                 | 3,159  | 0.16     |
|                      | No                  | 341    | 0.24     |

*Number at risk; †Expected risk of death
the outcome of these patients by primarily decreasing the rate of secondary cancers (Miralbell et al., 2002; Cohen et al., 2005; DeLaney, 2007; Kuhlthau et al., 2012). The high under-staging rates may have prevented patients from selecting definitive local therapy. The poor rates of radiotherapy after surgery use may have contributed to the poor outcome in these patients with this aggressive disease.

References

Amirian ES, Armstrong TS, Gilbert MR, Scheurer ME (2012). Predictors of survival among older adults with ependymoma. J Neurooncol, 107, 183-9.

Bishop AJ, McDonald MW, Chang AL, Esiashvili N (2012). Infant brain tumors: incidence, survival, and the role of radiation based on Surveillance, Epidemiology, and End Results (SEER) Data. Int J Radiat Oncol Biol Phys, 82, 341-7.

Cheung R (2012). Poor treatment outcome of neuroblastoma and other peripheral nerve cell tumors may be related to under usage of radiotherapy and socio-economic disparity: a US SEER data analysis. Asian Pac J Cancer Prev, 13, 4587-91.

Cheung R, Altschuler MD, D’Amico AV, et al (2001a). ROC-optimization may improve risk stratification of prostate cancer patients. Urology, 57, 286-90.

Cheung R, Altschuler MD, D’Amico AV, et al (2001b). Using the receiver operator characteristic curve to select pretreatment and pathologic predictors for early and late post-prostatectomy PSA failure. Urology, 58, 400-5.

Cohen RJ, Curtis RE, Inskip PD, Fraumeni JF Jr (2005). The risk of developing second cancers among survivors of childhood soft tissue sarcoma. Cancer, 103, 2391-6.

D’Amico AV, Desjardin A, Chung A, et al. (1998). Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy. Cancer, 82, 1887-96.

DeLaney TF. (2007). Clinical proton radiation therapy research at the Francis H. Burr Proton Therapy Center. Technol Cancer Res Treat, 6, 61-6.

Hanley JA, McNeil BJ (1982). The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology, 143, 29-36.

Koshy M, Rich S, Merchant TE, et al (2011). Post-operative radiation improves survival in children younger than 3 years with intracranial ependymoma. J Neurooncol, 105, 583-90.

Kuhlthau KA, Pulsifer MB, Yeap BY, et al (2012). Prospective study of health-related quality of life for children with brain tumors treated with proton radiotherapy. J Clin Oncol, 30, 2079-86.

McGuire CS, Sainani KL, Fisher PG (2009). Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study. J Neurosurg, 110, 725-9.

Miralbell R, Lomax A, Cella L, Schneider U (2002). Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J Radiat Oncol Biol Phys, 54, 824-9.

Rodriguez D, Cheung MC, Housri N, et al (2009). Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the Surveillance, Epidemiology, and End Results (SEER) database (1973-2005). J Surg Res, 156, 340-51.